AGEN: Agenus, Inc. Company Value to Net Income

Agenus, Inc - graphic logo of issuer AGEN

Agenus maintains significant pricing power in the cancer treatment segment due to the uniqueness of botensilimab. Business success relies on regulatory approvals and the outcomes of strategic alliances. This chart's price trend, featuring the 10.90 metric, reflects a high dependency on a single platform, which Agenus mitigates by selling rights to legacy developments to corporate behemoths.

Agenus Inc. (AGEN) Price to Earnings Ratio: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Agenus Inc (AGEN)

- price and consensus price forecast:
Stock Price agenusbio.com|AGEN - Consensus Target
- market capitalization information:
Market Value Agenus Inc.|AGEN - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Agenus|AGEN - Company Book Value|Market Cap to Net Assets Ratio agenusbio.com|AGEN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Agenus|AGEN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Agenus, Inc|AGEN - Company Debts|Debt to Book Value Ratio Agenus Inc.|AGEN - Company Long-Term Debts|Short-Term Debt Agenus|Quick Ratio agenusbio.com
- earnings and market multiples details:
AGEN - Net Profit|Projected Net Profit Agenus|AGEN - P/E Multiple|Projected Price to Earnings Ratio Agenus, Inc.|AGEN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Agenus Inc.|AGEN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Agenus|AGEN - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months agenusbio.com|AGEN - Earnings growth in current year|Earnings growth forecast for next year Agenus
Comprehensive company analysis:agenusbio.com AGEN
Signature product of Agenus Inc

Agenus is scaling the global immuno-oncology market by creating complex antibody combinations to combat tumor resistance. These ambitions directly impact the estimated asset value, where the company's current P/E ratio is fixed at 10.90. This multiple measures the market premium for future growth by relating the share price to net income. Analyzing this metric allows for the determination of the business's degree of overvaluation relative to its fundamental earnings.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN: P/E Multiple|Market Cap to Net Income Ratio pharming.com PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings Upstream Bio, Inc. UPB|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|Immunome Bio - Price to Earnings Multiple|Gossamer Bio, Inc. - Price to Earnings Ratio|P/E Multiple kalvista.com KALV|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharma PVLA|SVRA: P/E Multiple|Rigel Corp (RIGL) - P/E Multiple|ANAB (AnaptysBio, Inc.) - P/E Multiple|ATXS - Market Cap to Net Income Ratio|P/E Multiple ENGN|RAPT - Market Cap to Earnings|Price to Earnings Ratio Aerovate Therapeutics JBIO|ACRS: Price to Earnings Multiple|KYTX - Price to Earnings Ratio|Market Cap to Net Income TLSA|CABA: P/E Multiple|Ventyx Biosciences Inc. - Company Value to Net Income|THTX (Theratechnologies Inc) - P/E Multiple|P/E Multiple Avalo Therapeutics Inc|Price to Earnings Ratio Eledon Pharmaceuticals (ELDN)|CLYM (climbbio.com) - Company Value to Net Income|Price to Earnings Ratio Zura Bio ZURA|ATYR - Price to Earnings Ratio|Adagene Corp - P/E Multiple|IMA - P/E Multiple|STTK (shattucklabs.com) - Price to Earnings Ratio|Equillium - Company Value to Net Income|CNTB (Connect Biopharma Holdings) - P/E Multiple|Immunic Inc (IMUX) - Business Payback Period|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|Price to Earnings Ratio inflarx.de IFRX|Price to Earnings Ratio X4 Pharmaceuticals XFOR|ACET - Price to Earnings Ratio|CELU: Price to Earnings Ratio|INMB - P/E Multiple|Barinthus Bio (BRNS) - Price to Earnings Ratio|Price to Earnings Multiple KZR|SABS (SAB Biotherapeutics) - P/E Multiple|Market Cap to Earnings akaritx.com AKTX|P/E Multiple ENLV|P/E Multiple q32bio.com (QTTB)|P/E Multiple GOVX (GeoVax Labs Inc)|Market Cap to Net Income Ratio Edesa Biotech Corp|iBio, Inc. - P/E Multiple|Market Cap to Earnings Carisma Therapeutics|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Multiple BOLT|Price to Earnings Ratio HCWB|P/E Multiple Aptevo|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|Business Payback Period aditxt.com|P/E Multiple GRI (GRI Bio)|P/E Multiple XORTX Therapeutics Inc XRTX|ReShape Lifesciences - P/E Multiple|Market Cap to Net Income Ratio Revelation Biosciences Corp (REVB)|INDP: P/E Multiple|Market Cap to Earnings scinai.com (SCNI)|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Multiple AFMD (Affimed Therapeutics)|Price to Earnings Ratio Allakos Inc. (ALLK)|HOOK: Market Cap to Net Income|P/E Multiple IGMS (IGM Biosciences)|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio